Literature DB >> 2285596

The androgen receptor: functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines.

J Trapman1, C Ris-Stalpers, J A van der Korput, G G Kuiper, P W Faber, J C Romijn, E Mulder, A O Brinkmann.   

Abstract

The growth of the majority of prostate tumors is androgen-dependent, for which the presence of a functional androgen receptor is a prerequisite. Tumor growth can be inhibited by blockade of androgen receptor action. However, this inhibition is transient. To study the role of the androgen receptor in androgen-dependent and androgen-independent prostate tumor cell growth, androgen receptor mRNA expression was monitored in six different human prostate tumor cell lines and tumors, which were grown either in vitro or by transplantation on (male) nude mice. Androgen receptor mRNA was clearly detectable in three androgen-dependent (sensitive) tumors and absent or low in three androgen-independent tumors. Growth of the LNCaP prostate tumor cell line can be stimulated both by androgens and by fetal calf serum. In the former situation androgen receptor mRNA expression is downregulated, whereas in the latter no effect on androgen receptor mRNA levels can be demonstrated. Sequence analysis showed that the androgen receptor gene from LNCaP cells contains a point mutation in the region encoding the steroid-binding domain, which confers an ACT codon encoding a threonine residue to GCT, encoding alanine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2285596     DOI: 10.1016/0960-0760(90)90429-o

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  9 in total

1.  Kinetic and thermodynamic characterization of dihydrotestosterone-induced conformational perturbations in androgen receptor ligand-binding domain.

Authors:  Ravi Jasuja; Jagadish Ulloor; Christopher M Yengo; Karen Choong; Andrei Y Istomin; Dennis R Livesay; Donald J Jacobs; Ronald S Swerdloff; Jaroslava Miksovská; Randy W Larsen; Shalender Bhasin
Journal:  Mol Endocrinol       Date:  2009-05-14

2.  Steroid-regulated growth of DDT1MF-2 cells is profoundly influenced by culture conditions.

Authors:  D J Lamb; M Ray
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-12       Impact factor: 2.416

Review 3.  Androgen signal transduction and prostatic carcinoma.

Authors:  H Klocker; Z Culig; F Kaspar; A Hobisch; J Eberle; A Reissigl; G Bartsch
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

4.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer.

Authors:  J A Ruizeveld de Winter; P J Janssen; H M Sleddens; M C Verleun-Mooijman; J Trapman; A O Brinkmann; A B Santerse; F H Schröder; T H van der Kwast
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

Review 5.  Serially heterotransplanted human prostate tumours as an experimental model.

Authors:  Lluis-A Lopez-Barcons
Journal:  J Cell Mol Med       Date:  2009-10-29       Impact factor: 5.310

Review 6.  Importance of Estrogenic Signaling and Its Mediated Receptors in Prostate Cancer.

Authors:  Kin-Mang Lau; Ka-Fai To
Journal:  Int J Mol Sci       Date:  2016-08-31       Impact factor: 5.923

7.  Anti-proliferative effect and induction of apoptosis in androgen-independent human prostate cancer cells by 1,5-bis(2-hydroxyphenyl)-1,4-pentadiene-3-one.

Authors:  Kamini Citalingam; Faridah Abas; Nordin H Lajis; Iekhsan Othman; Rakesh Naidu
Journal:  Molecules       Date:  2015-02-17       Impact factor: 4.411

8.  Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptor.

Authors:  Srinivas Rajamahanty; Catherine Alonzo; Shahrad Aynehchi; Muhammad Choudhury; Sensuke Konno
Journal:  J Biomed Sci       Date:  2010-01-26       Impact factor: 8.410

Review 9.  Androgen therapy and atherosclerotic cardiovascular disease.

Authors:  K-C Y McGrath; L S McRobb; A K Heather
Journal:  Vasc Health Risk Manag       Date:  2008
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.